This poster was presented at the 29th Annual U.S. Psychiatric & Mental Health Congress, held October 21-24, 2016, in San Antonio, Texas.
Objective: To describe patients with major depressive disorder (MDD) switching to vortioxetine, and examine healthcare resource use and costs in the 6-month periods before and after switching therapy from another antidepressant treatment.
Methods: US claims data (2010-2015) from Integrated Dataverse (Symphony Health Solutions) from adults (≥18 years) with MDD (≥2 diagnoses records) who were treated with vortioxetine (≥1 prescription) were examined. The index date was the switch date (prescription fill) from another antidepressant (≥1 prescription) to vortioxetine. Healthcare resource use and costs were compared for 6-month pre-index vs post-index periods.
Results: Among patients with MDD switching to vortioxetine (N=22,606), 74.0% were women and the mean ± SD age was 48±14 years; 74.3% had a commercial healthcare plan. The most common comorbidity diagnoses recorded in the 12-month pre-index period were anxiety disorders (12.8%) and substance-related disorders (12.2%); 68.4% of patients had no recorded comorbidities. In the 12-month pre-index period, 49.1% of patients used 1 antidepressant and 44.5% used 2 or 3 antidepressants; most commonly used were selective serotonin reuptake inhibitors (47.6%) and serotonin-norepinephrine reuptake inhibitors (27.4%). For the 6-month post-index vs pre-index periods, numerical differences were seen in the proportion of patients with ≥1 visit to a mental health professional (23.8% vs 25.3%), mean ± SD number of visits (1.2±4.0 vs 1.5±4.5), mean ± SD total healthcare costs ($9059±16,361 vs $10,508±24,791), and mean ± SD pharmacy costs ($3680±4792 vs $2371±4125).
Conclusions: Decreased healthcare resource use and total healthcare costs were found after switching from another antidepressant to vortioxetine.